The estimated Net Worth of Konstantin Konstantinov is at least 2.03 千$ dollars as of 19 January 2023. Dr Konstantinov owns over 2,800 units of Codiak BioSciences stock worth over 160$ and over the last 4 years he sold CDAK stock worth over 1,873$.
Sign up
Dr Konstantinov CDAK stock SEC Form 4 insiders trading
Dr has made over 4 trades of the Codiak BioSciences stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 9,364 units of CDAK stock worth 1,873$ on 28 March 2023.
The largest trade he's ever made was selling 9,364 units of Codiak BioSciences stock on 28 March 2023 worth over 1,873$. On average, Dr trades about 2,320 units every 55 days since 2021. As of 19 January 2023 he still owns at least 2,800 units of Codiak BioSciences stock.
You can see the complete history of Dr Konstantinov stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Konstantin Konstantinov biography
Dr. Konstantin Konstantinov is the Chief Technology Officer at Codiak BioSciences.
How old is Dr Konstantinov?
Dr Konstantinov is 63, he's been the Chief Technology Officer of Codiak BioSciences since . There are 1 older and 7 younger executives at Codiak BioSciences. The oldest executive at Codiak BioSciences, Inc. is Richard Brudnick, 64, who is the Chief Bus. Officer & Head of Corp. Strategy.
What's Dr Konstantinov's mailing address?
Konstantin's mailing address filed with the SEC is C/O REPLIGEN CORPORATION, 41 SEYON ST., BLDG 1, STE 100, WALTHAM, MA, 02453.
Insiders trading at Codiak BioSciences
Over the last 4 years, insiders at Codiak BioSciences have traded over 15,220$ worth of Codiak BioSciences stock and bought 11,821,475 units worth 20,798,957$ . The most active insiders traders include Steven Gillis、Venture Fund Viii, L.P.Arch...、Permanent Fund Corp Alaska. On average, Codiak BioSciences executives and independent directors trade stock every 25 days with the average trade being worth of 19,158$. The most recent stock trade was executed by Yalonda Howze on 30 March 2023, trading 1,628 units of CDAK stock currently worth 326$.
What does Codiak BioSciences do?
Codiak BioSciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing exosome-based therapeutics for the treatment of oncology, neuro-oncology, neurology, neuromuscular diseases, infectious diseases, and other diseases. Its lead product candidates are exoSTING and exoIL-12 exosome therapeutic candidates for the treatment of various solid tumors. The company is also developing exoASO-STAT6, an antisense oligonucleotide targeting the STAT6 transcription factor; and exoVACC, a modular platform for constructing precision vaccines. It has a collaboration agreement with the Jazz Pharmaceuticals Ireland Limited, Sarepta Therapeutics, Inc., Kayla Therapeutics S.A.S., Washington University, Ragon Institute of MGH, MIT, and Harvard. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
What does Codiak BioSciences's logo look like?
Complete history of Dr Konstantinov stock trades at Repligen、Codiak BioSciences
Codiak BioSciences executives and stock owners
Codiak BioSciences executives and other stock owners filed with the SEC include:
-
Dr. Douglas Edward Williams Ph.D.,
Pres, CEO & Director -
Dr. Sriram Sathyanarayanan Ph.D.,
Chief Scientific Officer -
Yalonda Howze,
Exec. VP, Chief Legal Officer, Chief Compliance Officer & Corp. Sec. -
Dr. Benny Sorensen M.D., Ph.D.,
Member of Scientific Advisory Board & Consultant -
Dr. David J. Mauro M.D., Ph.D.,
Chief Medical Officer -
Dr. Benny Sorensen,
Member of Scientific Advisory Board & Consultant -
Richard Brudnick,
Chief Bus. Officer & Head of Corp. Strategy -
Nicole Barna,
Sr. VP of HR -
Christopher J. M. Taylor,
VP of Investor Relations & Corp. Communications -
Dr. Konstantin Konstantinov,
Chief Technology Officer -
Linda Cathavina Bain CPA,
CFO & Treasurer -
Arundathy N. Pandite,
Director -
Anne Virginie Eggimann,
Director -
Ventures Fund V General Par...,
-
Richard Brudnick,
See Remarks -
Venture Fund Viii, L.P.Arch...,
-
Charles L Cooney,
Director -
Kyriazi Theo Melas,
Director -
Briggs Morrison,
Director -
Eric S Lander,
Director -
Jason Haddock,
Director -
Karen Bernstein,
Director -
Steven Gillis,
Director -
Permanent Fund Corp Alaska,
-
Benny Sorensen,
See Remarks -
Nicole Barna,
See Remarks -
Jennifer J. Wheler,
Chief Medical Officer -
Ajay Verma,
See Remarks -
David J Mauro,
Chief Medical Officer -
Douglas E Williams,
President & CEO -
Konstantin Konstantinov,
Chief Technology Officer -
Linda Bain,
Chief Financial Officer -
Sriram Sathyanarayanan,
Chief Scientific Officer -
Yalonda Howze,
See Remarks